| Surprise Health And Rehabilitation Center | |
| 14660 W Parkwood Drive, Surprise, Arizona 85374 | |
| (623) 546-5030 | |
| Name | Surprise Health And Rehabilitation Center |
|---|---|
| Location | 14660 W Parkwood Drive, Surprise, Arizona |
| Certified By | Medicare |
| No. of Certified Beds | 100 |
| Occupancy Rate | 70.4% |
| Medicare ID (CCN) | 035297 |
| Legal Business Name | Ludden Healthcare, Inc. |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1487215067 |
| Organization Name | LUDDEN HEALTHCARE LLC |
| Doing Business As | SURPRISE HEALTH AND REHABILITATION CENTER |
| Address | 14660 W Parkwood Dr, Surprise, AZ 85374 |
| Phone Number | 602-883-3465 |
News Archive
Roflumilast, a drug recently approved in the United States to treat severe chronic obstructive pulmonary disease (COPD), increases the production of a protein that causes inflammation, which possibly results in patients developing a tolerance to the drug after repeated use and makes the drug less effective, according to researchers at Georgia State University, Kumamoto University and the University of Rochester Medical Center.
BioClinica, Inc., a global provider of clinical trial management services, announced today that Sanofi, one of the world's largest pharmaceutical companies, has selected BioClinica's OnPoint as the company's standard CTMS (Clinical Trial Management System).
Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today announced that it has closed its acquisition of CardiAQ Valve Technologies, Inc., a privately held company and developer of a transcatheter mitral valve replacement system. Edwards announced last month that it had signed an agreement to acquire CardiAQ.
By analyzing medical records of 901 adults who had surgery for a certain type of precancerous pancreatic cyst, researchers at Johns Hopkins Medicine and The Karolinska Institute in Sweden have updated parameters for an anatomical "marker" that can tell more precisely if these cysts are likely to develop into lethal pancreatic cancers.
› Verified 3 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Roflumilast, a drug recently approved in the United States to treat severe chronic obstructive pulmonary disease (COPD), increases the production of a protein that causes inflammation, which possibly results in patients developing a tolerance to the drug after repeated use and makes the drug less effective, according to researchers at Georgia State University, Kumamoto University and the University of Rochester Medical Center.
BioClinica, Inc., a global provider of clinical trial management services, announced today that Sanofi, one of the world's largest pharmaceutical companies, has selected BioClinica's OnPoint as the company's standard CTMS (Clinical Trial Management System).
Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today announced that it has closed its acquisition of CardiAQ Valve Technologies, Inc., a privately held company and developer of a transcatheter mitral valve replacement system. Edwards announced last month that it had signed an agreement to acquire CardiAQ.
By analyzing medical records of 901 adults who had surgery for a certain type of precancerous pancreatic cyst, researchers at Johns Hopkins Medicine and The Karolinska Institute in Sweden have updated parameters for an anatomical "marker" that can tell more precisely if these cysts are likely to develop into lethal pancreatic cancers.
› Verified 3 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|